Table 3 |
||||
|
Immunoexpression of the different markers in MBC, myofibroblastomas phyllodes tumor, and PASH |
||||
|
Antibody |
MBC (%) |
Myofibroblastoma (%) |
Phyllodes Tumor (%) |
PASH (%) |
|
|
||||
|
SNAIL |
34/34 (100%) |
4/4 (100%) |
14/14 (100%) |
7/8 (87.5%) |
|
EGFR |
34/34 (100%) |
0/4 (0%) |
13/14 (92.9%) |
8/8 (100%) |
|
OSCAR |
29/34 (85.3%) |
0/4 (0%) |
2/14 (14.3%) |
0/8 (0%) |
|
WS-KER |
26/34 (76.5%) |
0/4 (0%) |
0/14 (0%) |
0/8 (0%) |
|
P63 |
23/34 (56.7%) |
0/4 (0%) |
0/14 (0%) |
0/8 (0%) |
|
|
||||
|
MBC = metaplastic breast carcinoma PASH = pseudoangiomatous stromal hyperplasia |
||||
|
Nassar et al. Diagnostic Pathology 2010 5:76 doi:10.1186/1746-1596-5-76 |
||||
